|
| |
|
When considering abatement strategies to remove bio-toxins, bio contaminants, insects, noxious weeds ... - Lance Winslow |
| |
|
The future look and propulsion of the UAV in the battlespace. Are you ready for this? - Lance Winslow |
| |
|
The National Organization for Rare Disorders (NORD) is a federation of more than 140 nonprofit volun ... - Aaron Hall |
| |
|
|
| |
|
The final report of the workshop, "Functional Consequences of Gene Expression in Health and Disease, ... - Aaron Hall |
| |
|
Why does the number 13 evoke feelings of uncertainty and uneasiness? Is it really an unlucky number? ... - Bonnie Moss |
| |
|
Theoretical cosmologists spend much of their time perfecting what is now known as the 'Big Bang' the ... - Michael Strauss |
| |
|
I offer these as a metaphysical exposition of the basic dimensions defining space/time as we experie ... - LariAnn Garner |
| |
|
The most exact definition of Solar Energy is plainly ?C ??the energy from the sun??. It is a term us ... - Taylor Descar |
| |
|
| |
|
|
In a national effort, researchers in the Prostate Cancer Consortium, sponsored by the CaP CURE foundation, are building on the progress, accomplishments, and infrastructure of the Human Genome Project to find the gene for the most common cancer of American men. Prostate cancer caused an estimated 40,400 deaths in 1995, and 244,000 new cases were diagnosed.
Headed by Leroy Hood [University of Washington, Seattle (UWS)], an investigator in the Human Genome Project, the consortium's goals are to differentiate various forms of prostate cancer, determine the most effective methods of treatment for each, and eventually find a cure.
CaP CURE (Cure of Cancer of the Prostate) was founded in 1992 by Michael Milken after the former financier was diagnosed with the disease.
The consortium will identify and study families with an abnormally high incidence of prostate cancer, acquire and store high-quality prostate tissues for research, and support genetic and linkage studies leading to identification of the prostate cancer genes. Xenograft models will be used to develop extensive cDNA libraries of potential diagnostic and therapeutic compounds.
Participating consortium institutions and their research functions are listed below.
Tissue Banks: Dana Farber Cancer Institute, Boston; University of Texas M.D. Anderson Cancer Center, Houston; Washington University School of Medicine, St. Louis; and UWS
Epidemiology: Fred Hutchinston Cancer Center, Seattle
Genetic Mapping: Fred Hutchinson Cancer Center; Whitehead Institute MIT Center for Genome Research
Expression Mapping: UWS; University of California, Los Angeles |
| Author: Aaron Hall |
| |
Author Bio:
|
|
 |
|
| |
Related Articles |
| |
An Untapped Source Of Eternal Energy: What Is Solar Energy?
|
| |
Where the Birds Don't Sing [Advance to Chapter One: A Night with Tequila]
|
| |
Las Vegas Schools Open New Schools and Hire New Teachers
|
| |
Teaching - A Survival Guide for Students and New Teachers (Part 4) Body language basics
|
| |
Pharmacy Certification Online
|
| |
Archaic Overachiever Thrives in Hostile Environments
|
| |
Hilton Head Conference Attendees Discuss Small Genome Sequencing Progress
|
| |
Second Private Human Genome Sequencing Project Under Way
|
| |
The Eleven Dimensions of Space/Time - Part II
|
| |
Fourth Transcribed Sequences Workshop Held
|
| |
|
|
|
|
Main
